for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cytokinetics, Inc.

CYTK.O

Latest Trade

36.16USD

Change

0.66(+1.86%)

Volume

784,613

Today's Range

35.02

 - 

37.06

52 Week Range

16.05

 - 

42.87

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.50
Open
35.66
Volume
784,613
3M AVG Volume
18.22
Today's High
37.06
Today's Low
35.02
52 Week High
42.87
52 Week Low
16.05
Shares Out (MIL)
83.88
Market Cap (MIL)
2,977.85
Forward P/E
-10.60
Dividend (Yield %)
--

Next Event

Q4 2021 Cytokinetics Inc Earnings Release

Latest Developments

More

Cytokinetics Reports Third Quarter 2021 Financial Results

Cytokinetics Q2 Loss Per Share $0.86

Cytokinetics Announces Pricing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Industry

Biotechnology & Drugs

Contact Info

280 E Grand Ave

SOUTH SAN FRANCISCO, CA

94080-4808

United States

+1.650.6243000

http://cytokinetics.com/

Executive Leadership

Leonard Patrick Gage

Independent Chairman of the Board

Robert I. Blum

President, Chief Executive Officer, Director

Ching W. Jaw

Chief Financial Officer, Senior Vice President

David W. Cragg

Chief Human Resources and Administration Officer

Andrew Callos

Executive Vice President, Chief Commercial Officer

Key Stats

1.90 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.1K

2021(E)

0.0K
EPS (USD)

2018

-1.950

2019

-2.110

2020

-1.970

2021(E)

-3.348
Price To Earnings (TTM)
--
Price To Sales (TTM)
138.18
Price To Book (MRQ)
11.96
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
56.61
LT Debt To Equity (MRQ)
49.83
Return on Investment (TTM)
-38.33
Return on Equity (TTM)
-35.14

Latest News

Latest News

BRIEF-FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure

* FDA GRANTS FAST TRACK DESIGNATION FOR OMECAMTIV MECARBIL IN HEART FAILURE

BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.66

* Q1 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA

BRIEF-Cytokinetics - Co, Astellas Pharma Entered Two Agreements, Which Amend And Restate Co's Research, Development Commercialization Collaboration

* CYTOKINETICS - CO, ASTELLAS PHARMA INC. ENTERED TWO AGREEMENTS, WHICH AMEND AND RESTATE CO'S RESEARCH, DEVELOPMENT COMMERCIALIZATION COLLABORATION

BRIEF-Cytokinetics Says Co Believes It Is On Track To Achieve Its Key Strategic Objectives For 2020

* CYTOKINETICS PROVIDES CLINICAL TRIALS AND BUSINESS UPDATE IN RESPONSE TO COVID-19 PANDEMIC

BRIEF-Cytokinetics Granted European Orphan Designation For Reldesemtiv For The Treatment Of Amyotrophic Lateral Sclerosis

* CYTOKINETICS GRANTED EUROPEAN ORPHAN DESIGNATION FOR RELDESEMTIV FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics Reports Q4 Loss Per Share $0.52

* Q4 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA

BRIEF-Cytokinetics Announces Preclinical Data For AMG 594 Presented At Keystone Symposium On Heart Failure

* CYTOKINETICS ANNOUNCES PRECLINICAL DATA FOR AMG 594 PRESENTED AT THE KEYSTONE SYMPOSIUM ON HEART FAILURE

BRIEF-Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

* AMGEN, CYTOKINETICS AND SERVIER ANNOUNCE CONTINUATION OF GALACTIC-HF FOLLOWING PLANNED INTERIM ANALYSIS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up